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Novel Mutations in Synaptic Transmission Genes
Suppress Neuronal Hyperexcitation in
Caenorhabditis elegans
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and Salvatore J. Cherra III,*,4
*Section of Neurobiology, Division of Biological Sciences, †Department of Cellular and Molecular Medicine, and ‡Howard
Hughes Medical Institute, University of California, San Diego, La Jolla, California 92093
ORCID ID: 0000-0002-9371-9860 (Y.J.)
ABSTRACT Acetylcholine (ACh) receptors (AChR) regulate neural circuit activity in multiple contexts. In
humans, mutations in ionotropic acetylcholine receptor (iAChR) genes can cause neurological disorders,
including myasthenia gravis and epilepsy. In Caenorhabditis elegans, iAChRs play multiple roles in the
locomotor circuit. The cholinergic motor neurons express an ACR-2-containing pentameric AChR (ACR-
2R) comprised of ACR-2, ACR-3, ACR-12, UNC-38, and UNC-63 subunits. A gain-of-function mutation in
the non-a subunit gene acr-2 [acr-2(gf)] causes defective locomotion as well as spontaneous convulsions.
Previous studies of genetic suppressors of acr-2(gf) have provided insights into ACR-2R composition and
assembly. Here, to further understand how the ACR-2R regulates neuronal activity, we expanded the
suppressor screen for acr-2(gf)-induced convulsions. The majority of these suppressor mutations affect
genes that play critical roles in synaptic transmission, including two novel mutations in the vesicular ACh
transporter unc-17. In addition, we identified a role for a conserved major facilitator superfamily domain
(MFSD) protein, mfsd-6, in regulating neural circuit activity. We further defined a role for the sphingosine
(SPH) kinase (Sphk) sphk-1 in cholinergic neuron activity, independent of previously known signaling
pathways. Overall, the genes identified in our study suggest that optimal modulation of synaptic activity
is balanced by the differential activities of multiple pathways, and the novel alleles provide valuable
reagents to further dissect neuronal mechanisms regulating the locomotor circuit.
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Cholinergic transmission underlies a variety of processes including
learning,memory, andmovement. iAChRs are evolutionarily conserved
pentameric channels that regulateneuronal activity in the centralnervous
system and at the neuromuscular junction (Albuquerque et al. 2009).
Multiple mutations in the human iAChR subunits encoded by CHRNA2
(a2), CHRNA4 (a4), and CHRNB2 (b4), have been linked to autosomal
dominant forms of epilepsy (Boillot and Baulac 2016). Most disease-
associated mutations in a2, a4, or b4 cluster in the second or third
transmembrane (TM) domain and generally elicit gain-of-function phe-
notypes (Bertrand et al. 2002, 2005; Leniger et al. 2003; Hoda et al. 2008).
The Caenorhabditis elegans genome encodes over 30 AChR sub-
units (Hobert 2013). Decades of study have revealed the subunit com-
position of heteromeric and homomeric channels that act in different
tissues or cells and that display differences in channel physiology and
pharmacology. We previously characterized the ACR-2R pentameric
ion channel that is expressed in cholinergic motorneurons (Jospin et al.
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2009). A V309M gain-of-function mutation in the second TM domain
of the ACR-2 subunit causes elevated cholinergic activity. Additionally,
acr-2(gf) results in a cell nonautonomous decrease in the activity of in-
hibitoryGABAergic neurons (Jospin et al. 2009; Stawicki et al. 2011). The
concurrent increase in cholinergic excitation and decrease in GABA in-
hibition results in overexcitation of the motor circuit. This activity im-
balance causes defective locomotion accompanied by spontaneous
contractions of the body wall muscles, referred to as convulsions. Pre-
vious studies of genetic mutations that restored wild-type locomotion to
acr-2(gf) animals identified UNC-38, UNC-63, and ACR-12 as the other
subunits that form functional receptors with ACR-2 (Jospin et al. 2009).
Additional suppressors of the acr-2(gf) convulsion phenotype defined a
divalent cation transient receptor potential channel subfamilyM (TRPM)
that modulates locomotor circuit via ion homeostasis, and a novel mu-
tation in unc-13 that affects synaptic transmission through positional
docking of synaptic vesicles (Stawicki et al. 2011; Zhou et al. 2013).
To further characterize the molecular pathways that mediate the
effects of the overactive ACR-2R(gf), we expanded the genetic sup-
pressor screen of acr-2(gf). Here, we report the identification of novel
mutations in multiple genes that regulate synaptic transmission.
Many mutations are partial loss-of-function alleles in genes required
for synaptic function. We identified multiple mutations affecting a
conserved MFSD protein, mfsd-6. In addition, our analysis of sphk-1,
the C. elegans homolog of human Sphk, suggests a neuronal subtype
specific role for this kinase in promoting cholinergic activity in acr-2(gf)
animals. This screen expands our understanding of the function of
AChRs and provides a useful resource to dissect how synaptic trans-
mission is modulated in the context of an in vivo neural circuit.
MATERIALS AND METHODS
C. elegans genetics and mutagenesis screen
Strains were maintained at room temperature or 20 as described
(Brenner 1974). Genetic crosses were performed using standard meth-
ods. The genotypes of strains are listed in Supplemental Material, Table
S1. The previous suppressor mutations of acr-2(gf) were selected based
on faster movement than acr-2(gf) (Jospin et al. 2009). Here, we per-
formed a semiclonal screen, focusing on mutations that primarily re-
duced the convulsion frequency. Briefly, acr-2(n2420gf) L4 animals
(CZ10402) were subjected to 50 mM ethyl methanesulfonate following
standard protocols (Kutscher and Shaham 2014). Forty P0 animals were
placed on individual plates to allow egg-laying for 24 hr, averaging 30–50
F1 per P0. The P0 animals were transferred to fresh plates every day for
3 d, giving rise to20,000 mutagenized haploid genomes. The F2 prog-
eny were screened for a reduction in convulsion frequency. Only one line
derived from an individual P0 was kept for subsequent analysis, resulting
in a total of 31 lines. Since levamisole-resistant mutations were overrep-
resented in the previous screen (Jospin et al. 2009), we first tested the
suppressor mutations for levamisole sensitivity. Eight lines were found to
be resistant to 1mM levamisole and were not pursued in further analysis.
Mutation identification by outcrossing and
whole-genome sequencing
Twenty-three suppressor lines that showed normal sensitivity to leva-
misole were outcrossed to N2. Three suppressor mutations were linked
to the X-chromosome and were identified to be one intragenic loss-of-
function mutation of acr-2(gf) and two loss-of-function mutations in
acr-12. These suppressor lines were not subjected to further analysis.
We obtained whole-genome sequencing data on 20 outcrossed sup-
pressor strains. The Galaxy platform (Afgan et al. 2016) was used to
analyze raw sequence files with a custom-designed workflow. We used
custom-designed software to identify SNPs affecting restriction enzyme
sites in the mutagenized suppressor strains compared to the reference
N2 sequences. These SNPs were then used to follow chromosome
linkage after further outcrossing of the suppressors to N2 (Table S2).
For example, for mapping sphk-1(ju831), all of the outcrossed strains
contained a SNP on chromosome II but not SNPs on chromosome III
or IV. For mapping the unc-63(ju815) allele, CZ24017 (Table S2) was
outcrossed to N2, and linkage of the ju815mutation to chromosome I
was determined based on cosegregation of the suppression effect with
the unc-63 SNP and a SNP in anc-1(I),1.36map units from the unc-63
(I) locus (Table S1). Multiple outcrossings of unc-63(ju815) were then
conducted to eliminate other SNPs nearby to generate CZ25251.
Among the remaining 20 independent lines, only unc-63(ju815)
behaved as a completely dominant suppressor of acr-2(gf). To outcross
the unc-63(ju815) mutation, wild-type males heterozygous for an in-
tegrated fluorescent transgene, either (juIs76) or (juIs14), were crossed
into the ju815; acr-2(gf) strain. The fluorescent transgenes were used to
verify isolation of suppressed cross progeny. Nonconvulsing F2s were
isolated from heterozygous F1s carrying either juIs14 or juIs76 trans-
genes and verified as homozygous for the acr-2(gf)mutation by Sanger
sequencing. Using the combination of whole-genome sequencing and
SNP mapping analyses, we identified the causative mutations in all but
two of the 20 levamisole-sensitive suppressor lines. Both ju807 and
ju863 showed linkage to chromosome II; however, the causative mu-
tations have not been determined (Table S2).
Convulsion behavioral observation and
pharmacological analysis
All behavioral observations were made on mutations that were out-
crossed with N2 at least four times. Convulsions were defined as
simultaneous contraction of the body wall muscles producing a con-
certed shortening in body length. The convulsion frequency for d1 adult
animals was calculated during a 90 sec period of visual observation.
For levamisole sensitivity, 10d1adult animalswere transferred to fresh
plates containing 1mM levamisole and weremonitored every 15min for
paralysis. For aldicarb sensitivity, 0.5 mM aldicarb was used for strains
containing acr-2(gf) or mfsd-6 alleles, and 1.5 mM aldicarb was used on
all other strains. Aldicarb sensitivity was assessed by transferring 10 d1
adults to fresh aldicarb plates, and by monitoring worms for paralysis
every 30 min by gently touching the animal with a platinum wire. Aldi-
carb sensitivity was quantified for at least three independent experiments.
Fluorescent microscopy and image analysis
SPHK-1::GFP (nuIs197) was analyzed by confocal microscopy (LSM710,
Zeiss) in wild-type and acr-2(gf) animals. The dorsal cord of L4 animals
was imaged under identical settings for all samples, as previously de-
scribed (Cherra and Jin 2016). Fluorescence intensity and area of each
punctum was measured from a 0.5 mm Z-plane using the Analyze
Particles function in NIH ImageJ.
Data availability
All reagents including strains and the diagnostic SNP analysis program
are available upon request. The authors state that all data necessary for
confirming the conclusions presented in the article are represented fully
within the article.
RESULTS AND DISCUSSION
To identify additional genes contributing to the acr-2(gf) convulsion
phenotype, we performed a semiclonal genetic suppressor screen for
worms that showed a reduction in convulsion frequency. Following
pharmacological tests using levamisole, an agonist of muscle iAChRs,
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and aldicarb, an acetylcholinesterase inhibitor, as well as outcrossing
and genetic mapping, we identified a total of 20 independent suppres-
sor lines that showed normal sensitivity to levamisole. Two loss-of-
function mutations affected the TRPM channel gtl-2 (Stawicki et al.
2011; Takayanagi-Kiya et al. 2016). One mutation, ju825, was charac-
terized as a gain-of-function mutation in the ACC family of ligand-
gated channel lgc-46 (Takayanagi-Kiya et al. 2016). Two suppressors
were loss-of-functionmutations in the neuronal calcium sensor protein
ncs-2 (Zhou et al. 2017). Two suppressors were mapped to chromo-
some II, but the causative mutations have yet to be identified (Table 1).
The 13 suppressors described here in detail can be organized into two
major categories: novel mutations in ACR-2R subunits, and mutations
that affect synaptic vesicle loading, exocytosis, or recycling (Table 1).
Novel mutations in iAChR subunits suppress acr-2(gf)
UNC-63 and UNC-38 are both ACh-binding a subunits of the ACR-
2R. We have previously identified multiple recessive alleles of unc-63
and unc-38 that suppress the acr-2(gf) convulsion frequency and also
show strong resistance to levamisole (Jospin et al. 2009). Here, we found
several levamisole-sensitive alleles of unc-63 and unc-38 that behaved as
recessive suppressors of acr-2(gf) (Table 1). The M150I mutation in
UNC-63 (ju860) and the G321R or P494H mutation in UNC-38
(ju852, ju857) showed disparate distribution throughout the receptors
(Figure 1, A and B). Thesemutationsmay either alter the binding of ACh
but not levamisole, or may alter the function of neuronal iAChRs but
only mildly affect the muscle iAChRs. Of particular note, for UNC-63,
animals harboring the C151Ymutation are resistant to levamisole (Lewis
et al. 1980) but the M150I mutants remain sensitive to levamisole, high-
lighting the importance of obtaining a deeper understanding of the
structure–function relationship of iAChR subunits.
While all other mutations in unc-63 or unc-38 were recessive for
suppression of acr-2(gf), the ju815 mutation in unc-63, which affects
TM2, acted in a dominant manner to suppress acr-2(gf) convulsion
frequency (Figure 1, A–C). We verified the dominant suppression of
ju815 following extensive outcrossing and reisolation (Figure 1C, Table
S1, and Table S2). unc-63(ju815) completely suppressed acr-2(gf) con-
vulsions but does not cause a noticeable defect in locomotion as com-
pared to unc-63 null alleles (Figure 1C, File S1, File S2, and File S7). To
more quantitatively compare unc-63(ju815) to an unc-63 null mutation,
unc-63(x37) (Lewis et al. 1980), we assayed these mutants for sensitivity
to levamisole. unc-63(ju815)mutants were not as resistant to levamisole
as unc-63(x37) animals, but unc-63(ju815) animals showed mild re-
sistant to levamisole as compared to wild-type (Figure 1D).
The highly conserved TM2 domain lines the receptor pore and is
critical for regulating the activity of iAChRs (Unwin 2005). The hetero-
meric nature of iAChRs presents a difficulty for understanding the
functional interactions of the subunits without disrupting the entire
receptor complex. The observation that unc-63(ju815) dominantly re-
duces acr-2(gf)-induced behavior yet does not show resistance to leva-
misole suggests that the requirement for the UNC-63 a subunit in
neuronal ACR-2R and muscle Lev-R may differ significantly to provide
different gating properties or ion flux. Together with the missense mu-
tations that were reported previously to be resistant to levamisole (Jospin
et al. 2009), these alleles provide useful information to further tease apart
how heteromeric iAChRs with similar subunit compositions can have
separate functions to regulate neural circuit and muscle activity.
Novel mutations in presynaptic proteins
suppress acr-2(gf)
Several suppressors affected a set of genes that are required to maintain
the efficient transmission of neurotransmitters or neuropeptides. We
found ju874 to be an allele of unc-13, which is a phorbol ester/
diacylglycerol-binding protein with multiple C2 domains (Maruyama
and Brenner 1991). UNC-13 and itsMunc13 homologs are presynaptic
active zone proteins required for synaptic vesicle priming, and loss of
unc-13 greatly reduces synaptic transmission (Aravamudan et al. 1999;
Augustin et al. 1999; Richmond et al. 1999). We previously reported
that both strong loss-of-function mutations of unc-13 and a unique
mutation in the C2A domain of UNC-13 suppress convulsions of
acr-2(gf) (Zhou et al. 2013). The ju874 allele disrupts the splice site
between intron 26 and exon 27 and would be predicted to affect the
extreme C-terminus of the protein (Table 1). unc-13(ju874) behaved as
partial loss-of-function, as the animals show normal locomotion.
The ju873 mutation affects unc-41, the C. elegans Stoned B homo-
log, which is generally agreed to function in synaptic vesicle recycling
(Walther et al. 2004; Diril et al. 2006; Mullen et al. 2012). The unc-41
gene produces two isoforms: the A isoform is broadly expressed in the
nervous system, while the B isoform is exclusively expressed in GABA
motor neurons (Mullen et al. 2012). The unc-41(ju873) allele
results in a premature stop codon in the first exon of the A isoform
(Figure 2A and Table 1). While unc-41 null mutations are not lethal,
they cause multiple defects in locomotion and egg-laying (Mullen
et al. 2012). We confirmed that ju873 is a new allele of unc-41 through
complementation tests with a null allele, unc-41(e268). Consistent with
unc-41(ju873) being partial loss-of-function, the locomotion defects of
unc-41(ju873) are less severe than for unc-41(e268) (File S3 and File S4).
Interestingly, unc-41(e268); acr-2(gf) and unc-41(ju873); acr-2(gf) ani-
mals displayed strongly reduced convulsion frequencies (Figure 2B),
suggesting that the function of the UNC-41A isoform is rate-limiting
for synaptic transmission in acr-2(gf).
Consistent with our previous studies that revealed neuropeptide
modulation of acr-2(gf) (Stawicki et al. 2013; Zhou et al. 2013), we iden-
tified ju818 to be a new allele of unc-31, the calcium-dependent secretion
activator (Table 1). unc-31(ju818) causes a premature termination in all
n Table 1 acr-2(gf) suppressors
Gene Allele
Nucleotide
Changea
Amino Acid
Changeb
AChR subunits
unc-38 ju852 cCc/cAc P494H
unc-38 ju857 Gga/Aga G321R
unc-63 ju860 atG/atA M150I
unc-63 ju815 tGt/tAt C294Y
Synaptic genes
unc-31 ju818 Cga/Tga R1180
sphk-1 ju831 Cca/Tca P177S
unc-17 ju840 tCc/tTc S398F
unc-17 ju854 Ccc/Tcc P415S
unc-41 ju873 ctG/ctA Q91
unc-13 ju874 atttcaGcttccttg/
atttcaActtccttg
Splice site: intron
26/exon 27
mfsd-6 ju833 Gga/Aga G524R
mfsd-6 ju866 gGa/gAa G421E
mfsd-6 ju870 ttG/ttA Q76
Unidentified
ju807(II)
ju863(II)
AChR, acetylcholine receptor.
a
Capital letters indicate mutated nucleotide. The left is the reference sequence
and on the right, is the mutated sequence. For the ju874 mutation, underlined
sequence is intronic sequence prior to splice site.
b
Amino acid position is based on that for protein isoform UNC-31B, UNC-41A,
UNC-13A, respectively.
indicates stop codon.
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but one predicted isoform, and behaves as a null allele of unc-31 based on
the suppression of acr-2(gf).
In addition to genes that directly regulate synaptic vesicle release and
recycling,wehave also identified twomutations affectingunc-17 (Figure
2, C and D and Table 1), the C. elegans vesicular ACh transporter
(VAChT). Null alleles of unc-17 are lethal, and most strong loss-of-
function mutants are extremely defective in locomotion and growth.
The unc-17 mutants isolated from our screen behave as hypomorphs
and show essentially normal locomotion (File S5 and File S6). The new
alleles of unc-17 map to the region around TM11, which contains one
previously reported partial loss-of-function mutation, Y400N, isolated
in aldicarb resistance screens (Figure 2C) (Zhu et al. 2001). A previous
study of unc-17 mutations affecting TM domains has used pharyngeal
pumping or animal thrashing assays to rank mutation severity: TM9
mutations . TM6 mutations . TM5 mutations $ TM10 mutations
(Zhu et al. 2001). The new alleles, ju840 and ju854, reside in TM11, and
are similar to or slightly weaker than mutations in TM5 or TM10 based
on pharyngeal pumping (data not shown), thus placing these alleles at the
lower end of the severity spectrum. Previous transport activity analysis of
unc-17 mutations has led to the identification of the binding site for
vesamicol, a VAChT antagonist (Zhu et al. 2001). The alleles isolated
here will provide additional coverage to further understand howVAChT
functions to transport ACh and how this transporter is modulated.
Overall, reduction-of-functionmutations in genes involved in either
SV loading, release, or endocytosis are strong suppressors of acr-2(gf)
phenotypes, likely through reducing the efficiency of neurotransmission.
Loss-of-function in a novel conserved MFSD gene,
mfsd-6, suppresses acr-2(gf)
TheMFSD proteins are generally characterized by 10–12 TMs and play
broad roles as transporters in vesicular or plasma membranes (Yan
2013). Members of this family include GluT, VAChT, and VGAT.
We mapped three acr-2(gf) suppressor mutations to the R13A5.9 open
reading frame (Figure 3A). R13A5.9 displays . 23% identity to the
vertebrate protein known as MFSD6; therefore, this gene is renamed
mfsd-6. An independent mutation, tm3356, deletes 227 bases in exon
six, removing TM4, TM5, and part of TM6, and is therefore likely a null
mutation (Figure 3A). The tm3356 allele suppressed acr-2(gf) convul-
sion frequency to a similar degree as the point mutations isolated
in mfsd-6, which suggests that the suppression is due to loss-of-
function in mfsd-6 (Figure 3B). Animals harboring null mutations
in mfsd-6 were homozygous viable with no obvious locomotion
defects; however, these mutants were resistant to aldicarb, an acetyl-
cholinesterase inhibitor that causes eventual paralysis in wild-type an-
imals (Figure 3C). Similar results have been observed for a different
deletion allele of mfsd-6 (Ogurusu et al. 2015). Mutations in mfsd-6
Figure 1 Levamisole-sensitive unc-63 and unc-38
mutants suppress acr-2(gf). (A) Protein diagrams
illustrating known and new alleles of unc-63.
New alleles isolated in the acr-2(gf) suppressor
screen are indicated with a ju allele number.
G121R, K130I, and P159S were previously iso-
lated through an acr-2(gf) screen (Jospin et al. 2009),
and C151Y was isolated through a levamisole resis-
tance screen (Lewis et al. 1980). Levamisole-sensitive
alleles are labeled in black and levamisole-resistant
alleles are labeled in gray. unc-63(ju815) affects the
TM2 domain at a residue conserved fromC. elegans
to mammals. Protein alignments labeled as: C. e. =
C. elegansUNC-63,D.m. =Drosophilamelanogaster
ACH4, D. r. = Danio rerio ACHA2 and ACHB4,
and H. s. = Homo sapiens ACHA2 and ACHA6.
(B) Protein diagrams illustrating known and new
alleles of unc-38. P159L was previously isolated in
a levamisole resistance screen (Garcia et al. 2001),
and P111L, P267L, and G477E were previously iso-
lated in an acr-2(gf) suppressor screen (Jospin et al.
2009). Black and gray alleles indicate levamisole
sensitivity and resistance, respectively. Protein align-
ments labeled asC. e. =C. elegans UNC-38,D.m. =
Drosophila melanogaster ACH4, D. r. = Danio rerio
ACHA2 and ACHB2, and H. s. = Homo sapiens
ACHA2 and ACHA3. (C) unc-63(ju815) completely
suppresses acr-2(gf) convulsions. N $ 17. (D)
unc-63(ju815) does not cause strong resistance to
1 mM levamisole. unc-63(x37) results in a prema-
ture stop and is a null allele. N = 10 animals each
trial, average of three trials in shown.  P, 0.001,
two-way ANOVA followed by Bonferroni’s post
hoc test. aa, amino acid; TM, transmembrane.
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were not resistant to levamisole, suggesting thatmfsd-6mutants do not
display defects in muscle response to ACh. Since mutations in mfsd-6
prevent the paralysis caused by aldicarb, which causes a build-up of
ACh, leading to prolonged muscle contraction, we hypothesize that
mutations in mfsd-6 suppress the acr-2(gf) convulsions by disrupting
presynaptic release of ACh. MFSD-6 localizes to presynaptic terminals
in or near synaptic vesicles (Ogurusu et al. 2015). Therefore, we spec-
ulate that MFSD-6 may regulate synaptic vesicle trafficking or exocy-
tosis to enable efficient synaptic transmission.
The TMs of MFSD family transporters have been grouped into three
functional classes: substrate coordination, TM1, 4, 7, and 10; interdomain
interactions, TM2, 5, 8, and 11; and structural integrity, TM3, 6, 9, and
12 (Yan 2013). As found with UNC-17, the most severe unc-17mutants
fall in the structural TMs TM9 or TM6. Interestingly, our current screen
has identified mutations in both unc-17 andmfsd-6 that affect the inter-
domain interactions modulated by TM8 or TM11. There are currently
multiple hypotheses regarding how the MFSD family may transport
solutes (Quistgaard et al. 2016), and these novel mutations may provide
Figure 3 Loss-of-function in a novel conserved
major facilitator superfamily domain (MFSD)
gene,mfsd-6, suppresses acr-2(gf). (A) Diagram of
MFSD-6 protein with transmembrane (TM) do-
mains labeled in gray. Two of the mutations iden-
tified in this screen alter evolutionarily conserved
residues. Protein alignments labeled as: C. e. =
C. elegans MFSD-6, D. m. = Drosophila mela-
nogaster uncharacterized encoded by jef, D. r. =
Danio rerio MFSD6-A, and H. s. = Homo sapiens
MFSD6. (B) Loss-of-function in mfsd-6 suppresses
acr-2(gf) convulsions. N $ 8 worms per genotype
 P , 0.001,  P , 0.01, one-way ANOVA on
ranks followed by Dunn’s post hoc test. (C)mfsd-6
mutations cause aldicarb resistance. Percent of
animals not paralyzed over time on plates with
0.5 mM drug are shown. N = 10 animals in each
trial, average of four trials shown,  P , 0.001,
 P, 0.01, two-way ANOVA followed by Bonferroni’s
post hoc test.
Figure 2 Novel mutations that alter synaptic
vesicle function suppress acr-2(gf). (A) Gene struc-
tures of unc-41a and unc-41b isoforms are
depicted as described in (Mullen et al. 2012).
unc-41(ju873) causes a premature stop in the first
exon of unc-41a, which is broadly expressed in
the nervous system. unc-41(e268) is a premature
stop and is a null for both unc-41 isoforms, pro-
ducing no functional protein (Mullen et al. 2012).
(B) unc-41 loss-of-function suppresses acr-2(gf)
convulsions. N $ 19 each genotype.  P ,
0.001, one-way ANOVA on ranks followed by
Dunn’s post hoc test. n.s., not significant. (C) Di-
agram of UNC-17 protein with previously studied
aa changes in the UNC-17 protein labeled in gray
(Zhu et al. 2001). The mutations isolated in our
screen, both of which alter evolutionarily con-
served residues, are labeled in black. Protein
alignments labeled as: C. e. = C. elegans UNC-
17, D. m. = Drosophila melanogaster VAChT,
D. r. =Danio rerio VACh-B, andH. s. =Homo sapiens
VAChT. (D) unc-17(lf) mutations suppress acr-2(gf)
convulsion frequency. N $ 10  P , 0.001, One-
way ANOVA on ranks followed by Dunn’s post
hoc test. aa, amino acid; VAChT, vesicular ace-
tylcholine transporter.
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further insight into how these proteins function, for example by illumi-
nating the underlying structural changes that occur during solute trans-
port. Mammalian MFSD6 shows expression in many areas of the brain,
including the cortex, hippocampus, and midbrain [Allen Mouse Brain
Atlas, Lein et al. (2007)], and its in vivo function remains unknown.
Overall, the mutations in mfsd-6 provide a valuable entry point to in-
vestigate the function of this conserved protein family.
Loss-of-function mutations in sphk-1 suppress
acr-2(gf) hyperactivity
We identified the ju831mutation as affecting sphk-1, the sole C. elegans
homolog of the conserved Sphk, which phosphorylates the lipid SPH to
generate SPH-1-phosphate (S1P) (Spiegel andMilstien 2003). Previous
studies have shown that SPHK-1 is localized near presynaptic terminals
and that sphk-1 loss-of-function mutants exhibit a reduced evoked re-
lease from excitatory motor neurons, possibly by modulating synaptic
vesicle recycling (Chan et al. 2012; Chan and Sieburth 2012; Shen et al.
2014). sphk-1(ju831) causes a conserved P177S mutation in the kinase
domain, close to the ATP-binding site (Figure 4A). sphk-1(ju831)
strongly suppresses acr-2(gf) convulsion frequency, which was rescued
by expressing an SPHK-1 cDNA transgene driven by the endogenous
sphk-1 promoter (Figure 4B). The null allele, sphk-1(ok1097), sup-
pressed acr-2(gf) locomotion defects, but reduced convulsion frequency
to a lesser degree as compared to ju831 (Figure 4B), suggesting that
sphk-1(ju831) might act as a dominant-negative mutation.
Previous studies have found that sphk-1(ok1097) mutants are re-
sistant to 1.5 mM aldicarb as compared to wild-type (Chan et al. 2012).
sphk-1(ju831) animals also showed resistance to paralysis after 3 hr
incubation on 1.5 mM aldicarb, relative to wild-type animals (Fig-
ure 4C and Table S3). Consistent with being a dominant-negative
mutation, sphk-1(ju831) mutants are more resistant to aldicarb than
sphk-1(ok1097). Interestingly, we observed that overexpression of sphk-1
also induced aldicarb resistance to a similar level as sphk-1(ok1097),
suggesting that in these conditions, excessive levels of sphk-1 also in-
hibit neurotransmission. Overexpression of wild-type sphk-1 reduced
the aldicarb resistance of sphk-1(ju831) animals to that of the
overexpression line alone (Figure 4C). In contrast to sphk-1 mutants,
acr-2(gf) animals are hypersensitive to aldicarb (Jospin et al. 2009),
becoming paralyzed after just 1 hr on a lower concentration of drug,
0.5 mM (Figure 4D and Table S4). sphk-1(ju831) suppressed the
aldicarb hypersensitivity of acr-2(gf) animals back to wild-type levels
(Figure 4D). Transgenic overexpression of wild-type sphk-1 restored
aldicarb hypersensitivity to sphk-1(ju831); acr-2(gf) double mutants
(Figure 4D), indicating that sphk-1 is critical for regulating cholinergic
synaptic activity.
We have previously shown that the acr-2(gf)mutation is capable of
driving the convulsion phenotype when expressed under the unc-129
promoter in the cholinergic motorneurons that form synapses in the
dorsal cord (Qi et al. 2013). Interestingly, we found that expres-
sion of sphk-1 was also required only in this subset of cholinergic
Figure 4 Loss of sphk-1 function suppresses acr-
2(gf) phenotypes. (A) ju831 affects the kinase
domain of sphk-1. Shown is the sphk-1 genomic
locus and protein alignment of part of the kinase
domain. sphk-1(ju831) is G/A transition in the
fourth exon of the gene, causing a P177S muta-
tion. ok1097 is a large deletion and null allele.
Protein alignments labeled as: C. e. = C. elegans
SPHK-1, D. m. = Drosophila melanogaster Sphk1,
D. r. = Danio rerio Sphk1, and H. s. = Homo sapi-
ens Sphk1. (B) sphk-1(ju831) and sphk-1(ok1097)
both suppress acr-2(gf) convulsions. Transgenic
expression of SPHK-1 under its endogenous pro-
moter or the unc-129 promoter rescues sphk-
1(ju831) suppression of acr-2(gf). N $ 18 each
genotype  P , 0.001, n.s., not significant.
One-way ANOVA on ranks followed by Dunn’s
post hoc test. (C) sphk-1 mutations cause aldicarb
resistance. Shown are percentages of animals not
paralyzed after 3 hr on 1.5 mM aldicarb. (D) sphk-
1(ju831) suppresses acr-2(gf) aldicarb hypersen-
sitivity. Shown are the percentages of animals
that were not paralyzed after 1 hr on 0.5 mM
aldicarb. Pharmacological data are averaged from
at least three trials, N $ 9 animals per strain per
trial.  P , 0.001,  P , 0.01, n.s., not signifi-
cant, one-way ANOVA followed by Bonferroni’s
post hoc test. SPHK, sphingosine kinase.
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motorneurons to rescue the suppression effect of sphk-1(ju831) on
convulsion frequency of acr-2(gf) (Figure 4B). These data suggest that
SPHK-1 acts directly in the cholinergic neurons to mediate the con-
vulsion behavior of acr-2(gf) animals.
sphk-1 contributes to acr-2(gf) convulsions
independently of its regulatory Gqa pathway
In C. elegans motor neurons, activation of Gqa signaling, through
either treatment with arecoline, a muscarinic agonist, or by a gain-of-
function mutation in egl-30/Gqa, caused increased punctal expression
of SPHK-1::GFP in axons and increased sensitivity to aldicarb (Chan
et al. 2012, 2013; Chan and Sieburth 2012). The activity-induced
SPHK-1::GFP expression required a G-protein signaling pathway in-
volving the muscarinic receptor gene gar-3, the guanine exchanger
factor Trio unc-73, and a calmodulin-like calcium binding protein
calm-1 (Chan et al. 2012, 2013; Chan and Sieburth 2012). We wanted
to address whether the increased cholinergic activity caused by acr-2(gf)
might promote sphk-1 expression through the GAR-3 G-protein signaling
pathway. Therefore, we used genetic analyses to test whether this
pathway was required for acr-2(gf) convulsions, similar to sphk-1.
Double mutant combinations were made between gar-3 or calm-1
null alleles, or unc-73(ce362), a partial loss-of-function allele, and
acr-2(gf). None of these double mutants showed detectable suppression
of convulsions (Figure 5A), although calm-1(0); acr-2(gf) animals
showed a slight, but not statistically significant, increase in convulsion
rate. We next investigated whether functional redundancy from similar
receptors could mask a role for GAR-3 in the cholinergic neuron re-
sponse to acr-2(gf). To test this, we examined gar-2, which is also
expressed in the cholinergic motorneurons and is thought to inhibit
circuit activity through Goa signaling (Dittman and Kaplan 2008). We
found that both gar-2(0); acr-2(gf) and gar-2(0); gar-3(0); acr-2(gf)mu-
tants were not significantly different from acr-2(gf) alone (Figure 5A).
Altogether, these genetic data suggest that, while the activity of calm-1
or the G-protein signaling pathway regulates SPHK-1 localization and
function in a wild-type background, they are not necessary for sphk-1
function when cholinergic motor neurons are hyperactivated in
acr-2(gf) mutants.
Although the G-protein signaling pathway that regulates SPHK-1
localization did not affect acr-2(gf) convulsions, it was possible that
hyperactive ACR-2R caused by the acr-2(gf) mutation alters SPHK-1
localization through a parallel pathway to cause convulsions. Therefore,
we investigated the localization and fluorescence intensity of SPHK-1::GFP
in cholinergic motor neurons. Compared to wild-type, acr-2(gf) caused
a small but statistically significant decrease in SPHK-1::GFP fluores-
cence intensity without altering synapse number (Figure 5, A, B and C).
Therefore, unlike activation of Gqa signaling, which increased the
expression of SPHK-1 in cholinergicmotor neurons, hyperactivation of
the ACR-2R does not cause increased synaptic SPHK-1 levels.
Loss-of-function in SPH metabolism genes does not
affect acr-2(gf) convulsions
SPH can be converted to ceramide by ceramide synthase enzymes or to
S1P through the activity of Sphk (Figure 6A) (Spiegel andMilstien 2003;
Maceyka et al. 2012). Furthermore, S1P is irreversibly degraded by the
enzyme S1P lyase. sphk-1 is the sole Sphk homolog in C. elegans, and
sphk-1(lf) mutants should lack S1P. We next tested whether other
enzymes in the SPH metabolism pathway both upstream and down-
stream of SPHK-1, were involved in mediating acr-2(gf) behaviors.
Figure 5 SPHK-1 regulates acr-2(gf) convulsions independent of
known regulatory mechanisms. (A) Loss-of-function mutations in gar-2,
gar-3, unc-73, and calm-1 genes do not suppress acr-2(gf) convulsion
rate. N $ 19, n.s., not significant, one-way ANOVA on ranks followed
by Dunn’s post hoc test. (B) Expression of Punc-129::SPHK-1::GFP
in the dorsal cord of wild-type and acr-2(gf) animals. Bar, 10 mm.
(C) Quantification of SPHK-1::GFP punctal density. (D) Quantifica-
tion of SPHK-1::GFP intensity. N $ 19 each genotype. n.s., not sig-
nificant (P . 0.05),  P , 0.001, Student’s t-test. SPHK, sphingosine
kinase.
Figure 6 Mutations in sphingolipid metabolism genes do not mod-
ulate acr-2(gf) convulsions. (A) Diagram of the sphingosine metabolism
pathway with C. elegans homologs noted. (B) Loss-of-function muta-
tions in the sphingosine metabolism pathway do not suppress acr-2(gf)
convulsion rate. The hyl-1 and lagr-1mutations are small deletions that
disrupt the catalytic domains of these proteins (Deng et al. 2008),
while the tag-38 mutation is a large deletion resulting in a molecular
null. N $ 19, n.s., not significant, one-way ANOVA on ranks followed
by Dunn’s post hoc test. CDase, ceramidase.
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The C. elegans homologs of ceramide synthase include the genes
hyl-1 and lagr-1, while tag-38 encodes the worm S1P lyase homolog.
Lipid profiling has found that both hyl-1(lf) and sphk-1(ok1097)
mutants accumulate SPH, while hyl-1(lf) was also shown to cause
decreased levels of long-chain ceramides (Menuz et al. 2009). Both
tag-38 and hyl-1 are expressed in the C. elegans cholinergic motor
neurons, and TAG-38 strongly colocalizes with SPHK-1 in axons
(Chan and Sieburth 2012). Null or strong loss-of-function mutants of
tag-38 and hyl-1 are superficially wild-type, with normal locomotion,
although hyl-1(lf) animals are hypersensitive to aldicarb, possibly due to
increased SPH and S1P levels (Chan and Sieburth 2012). Given the
increased aldicarb sensitivity of hyl-1(lf)mutants, one prediction would
be that increased SPH and/or S1P levels resulting from hyl-1(lf) or tag-
38(0) might enhance acr-2(gf) phenotypes. However, we found that
neither tag-38(0) nor hyl-1(lf) had any effect on acr-2(gf) convulsion
rate (Figure 6B). In addition to hyl-1, the C. elegans genome contains
another putative ceramide synthase gene, lagr-1. Although no locomo-
tion phenotype has been reported for lagr-1(lf), this mutation conferred
resistance to radiation-induced apoptosis in the germline (Deng et al.
2008). In contrast, sphk-1(ok1097) results in increased radiation-induced
cell death in the germline. lagr-1(lf) was epistatic to sphk-1(ok1097) in
germline apoptosis due to lack of a ceramide, a proapoptotic lipid. How-
ever, we found that neither lagr-1(lf) nor lagr-1(lf); hyl-1(lf) had any
significant effect on acr-2(gf) convulsions (Figure 6B). Therefore, in-
creased SPH and S1P levels do not seem to affect acr-2(gf) convulsion
rate. These results are consistent with the observation that overexpression
of SPHK-1 also does not enhance convulsions (Figure 4B). Taken to-
gether, these genetic data highlight a novel, specific function of sphk-1 in
the motor circuit in the context of acr-2(gf) that may be independent of
the SPH metabolism pathway.
S1P has been shown to function primarily as a signaling molecule
that regulates multiple processes, particularly apoptosis, and has been
well-studied for its role in cancer (Maceyka et al. 2012). Some reports
from mouse models and cell culture studies also support a conserved
function for Sphk1 in promoting excitatory neurotransmission. Work
in murine models found a role for Sphk1 in excitatory transmission in
the hippocampus to promote learning and memory (Kanno et al.
2010). In cell culture experiments, Sphk1 localized to sites of endocy-
tosis, and knockdown of Sphk1 resulted in decreased rates of endocytic
uptake (Shen et al. 2014). These studies suggest that Sphk1 may func-
tion to mediate activity-dependent effects on endocytic recycling in the
nervous system. Coincidentally, our screen has revealed a selective role
of unc-41/stoned and sphk-1, both implicated in promoting endocyto-
sis, in modulating the effects of a hyperactive neuronal AChR in the
locomotion circuit. Future studies will explore possible links between
these pathways.
Conclusions
Neurologicaldisorders suchasepilepsyoftenresult fromhyperactivityof
cholinergic receptors, which can lead to disruptions in a diverse set of
genes and pathways. We have used C. elegans to understand how the
activity of neural circuits can be modulated in the context of circuit
hyperactivity. The primary effect of acr-2(gf) is increased cholinergic
release, and disruption of the ACR-2R itself (Jospin et al. 2009) or
components of presynaptic release machinery are key points to mod-
ulate acr-2(gf) phenotypes (Zhou et al. 2013). This is further supported
by the identification of novel hypomorphic alleles of genes, known to
function in presynaptic release in the cholinergic system, that strongly
suppress acr-2(gf). Our recent studies of another suppressor mutation
lgc-46(ju825) also revealed an ACC family of ligand-gated anion chan-
nels that localize to the presynaptic terminal and may provide rapid
feedback inhibition on synaptic vesicle release (Takayanagi-Kiya et al.
2016). Altogether, our findings demonstrate the power of genetic
pathway dissection using the suppression of acr-2(gf) as a functional
readout.
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